A number of targeted inhibitors of the MEK pathway have been investigated in the laboratory and clinical settings, with particular interest in the field of NSCLC due to the high rate of KRAS mutations in the disease. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.